Cannabics Pharmaceuticals (OTCQB: CNBX) announced significant results from an in vivo study of its drug candidate, RCC-33, for colorectal cancer. The study demonstrated a 33% reduction in tumor volume compared to control mice, achieving statistical significance with a p-value of ≤ 0.016. This outcome is pivotal in advancing their research and development within cannabinoid-based therapies, positioning Cannabics as a leader in cancer treatment innovation. The company’s operations are based in Israel, under the license from the Ministry of Health.
Cannabics Pharmaceuticals (OTCQB: CNBX) announced promising results from its in-vivo study on RCC-33 for colorectal cancer, showing a 33% reduction in tumor volume versus control (p ≤ 0.016). The study involved inoculated mice receiving daily doses of RCC-33, with significant differences noted after 10 days. The oncology therapeutics market is projected to reach $250 billion by 2024, with a focus on addressing a $10 billion colorectal cancer segment. Cannabics plans to prepare a product dossier for FDA submission and requests for a pre-IND meeting.
Cannabics Pharmaceuticals Inc. (OTCQB: CNBX) announced interim results from its ongoing in-vivo study of RCC-33, a drug candidate for colorectal cancer, revealing a 27% reduction in tumor volume after 12 days of treatment in nude mice compared to the control group. This significant result, with a p-value of 0.022, marks a promising development towards potential FDA approval. The study was initiated alongside the objective of improving survival rates for colorectal cancer patients, which currently stands at 67% for five-year survival with existing treatments.
Cannabics Pharmaceuticals (OTCQB: CNBX) announced the establishment of a dedicated division for its Antitumor Drug Candidate RCC-33, aimed at treating colorectal cancer. This move supports the company’s strategy to enhance clinical validation efforts, including in-vivo experiments and collaborations with medical centers. CEO Eyal Barad emphasized the significance of this initiative, while Medical Director Dr. Erez Scapa highlighted the potential positive impact of RCC-33 on colorectal cancer patients. Cannabics focuses on personalized cannabinoid therapies for cancer.